Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Futuximab/modotuximab - Symphogen

Drug Profile

Futuximab/modotuximab - Symphogen

Alternative Names: 992-and-1024; 992/1024; DS 992/DS 1024; DS-1024/DS-992; Modotuximab/futuximab; Sym-004

Latest Information Update: 22 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Symphogen
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Glioma
  • Phase I Non-small cell lung cancer
  • No development reported Head and neck cancer; Oesophageal cancer

Most Recent Events

  • 11 Apr 2019 Symphogen terminates a phase II trial for Colorectal cancer (Metastatic disease, Second-line therapy or greater) in USA, Germany, Spain and Italy due to administrative reasons (IV) (NCT03549338)
  • 31 Jan 2019 Symphogen withdraws a phase III trial prior to enrolment for Colorectal Cancer (Late-stage disease, Second-line therapy or greater) in Japan due to administrative reasons (IV) (NCT03717038)
  • 23 Oct 2018 Symphogen plans a phase III trial for Colorectal Cancer (Late-stage disease, Second-line therapy or greater) in February 2019 (IV) (NCT03717038)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top